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ABSTRACT
ObjectiveTo study howcompositeoutcomes, which have
combined several components into a single measure, are
defined, reported, and interpreted.
Design Systematic review of parallel group randomised
clinical trials published in 2008 reporting a binary
composite outcome. Two independent observers
extracted the data using a standardised data sheet, and
two other observers, blinded to the results, selected the
most important component.
Results Of 40 included trials, 29 (73%) were about
cardiovasculartopicsand24(60%)wereentirelyorpartly
industry funded. Composite outcomes had a median of
three components (range 2–9). Death or cardiovascular
death was the most important component in 33 trials
(83%). Only one trial provided a good rationale for the
choice of components. We judged that the components
were not of similar importance in 28 trials (70%); in 20 of
these, death was combined with hospital admission.
Othermajorproblemswerechangeinthedefinitionofthe
composite outcome between the abstract, methods, and
results sections (13 trials); missing, ambiguous, or
uninterpretable data (9 trials); and post hoc construction
of composite outcomes (4 trials). Only 24 trials (60%)
providedreliableestimatesforboththecompositeandits
components,andonlysixtrials(15%)hadcomponentsof
similar, or possibly similar, clinical importance and
provided reliable estimates. In 11 of 16 trials with a
statistically significant composite, the abstract
conclusion falsely implied that the effect applied also to
the most important component.
Conclusions The use of composite outcomes in trials is
problematic. Components are often unreasonably
combined, inconsistently defined, and inadequately
reported. These problems will leave many readers
confused, often with an exaggerated perception of how
well interventions work.
INTRODUCTION
A composite outcome consists of two or more compo-
nent outcomes. Patients who have experienced any
oneoftheeventsspecifiedbythecomponentsarecon-
sidered to have experienced the composite outcome.
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The main advantages supporting the use of a compo-
site outcome are that it increases statistical efficiency
because of higher event rates, which reduces sample
size requirement,costs, and time; it helps investigators
avoid an arbitrary choice between several important
outcomes that refer to the same disease process; and
it is a means of assessing the effectiveness of a patient
reportedoutcomethataddressesmorethanoneaspect
of the patient’s health status.
1-6
Unfortunately,compositeoutcomescanbemislead-
ing. This is especially true when treatment effects vary
across components with very different clinical
importance.
7 For example, suppose a drug leads to a
large reduction in a composite outcome of “death or
chest pain.” This finding could mean that the drug
resulted in fewer deaths and less chest pain. But it is
also possible that the composite was driven entirely
by a reduction in chest pain with no change, or even
an increase, in death.
Studies show that treatment effects often vary, and
typically, the effect is smallest for the most important
component and biggest for the less important
components.
358 Unless authors clearly present data
for all components and take care in how they discuss
compositefindings,itiseasyforreaderstoassumemis-
takenly that the treatment effect applies to all compo-
nents. In this study, we systematically examined how
composite outcomes were used and how well they
were reported in recent randomised trials.
METHODS
We performed a systematic review of parallel group
randomised clinical trials published in 2008 that had
a primary composite outcome. We excluded studies
where the composite was a secondary outcome mea-
sure and studies with more than two arms.
Search strategy
An iterative search strategy was developed, using var-
ious combinations of search terms and refining them
basedontheinitialcollectionoftrials.Furthermore,we
identified relevant terms from a previous review of
cardiovascular trials published between 2000 and
2006,
8 where the authors had hand searched 14 major
journals.ThefinalPubMedsearchwasdoneon26Jan-
uary2009.Welimitedthearticlestothosepublishedin
2008andcombined“random*”withoneormoreof31
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dropped two additional terms, “composed of”[tiab]
and “combination of”[tiab], as these were too unspeci-
fic, yielding 6255 and 14633 hits, respectively, when
combined with “random*.”
Study selection and data extraction
The abstracts were reviewed by one person (GC), and
potentially eligible articles were retrieved in full and
assessed independently by two coders (GC and HB).
Disagreements were resolved by discussion, and for
ambiguous cases the other authors were involved.
The two coders used a standard form to extract data
independently and collected data on journals, clinical
area, composite outcome and its components, and
source of funding.
One composite outcome was included per article.
When more than one such outcome was reported in
an article, we used a hierarchical selection process of
(a) authors’ explicit declaration of primacy, (b) the
composite outcome used to calculate the sample size,
(c) authors’ attribution of importance to the composite
outcome in their description of the results, or (d) the
composite outcome that appeared first in the methods
section.
Content analysis
Twopairsofindependentobserversusedstandardised
protocols to assess the definition and quality of report-
ing of the composite outcomes. Most judgments
involved assessments of facts (such as whether the
number of components making up the composite
changed within the paper). Here, disagreement was
almost entirely due to oversight, not a difference in
opinion. For the few subjective judgments, we created
simple and explicit rules to objectify the process as
much as possible. For example, we judged the conclu-
sion of abstracts as falsely suggesting that an effect on
thecompositealsoappliedtothemostimportantcom-
ponent (when it did not) if all components were listed
using“and”orifthe compositewasnamedasa classof
events. Our rules are provided when we present
results. Also, we provide examples to allow readers to
decide for themselves whether our judgments were
reasonable. We resolved discrepancies involving
facts and disagreements by discussion.
Composite definition Two observers (PCG, and LS or
SW) independently and blinded to the results selected
the mostimportantcomponent ofeach compositeout-
come, taking into account the hierarchy for analysing
composite outcomes proposed by Lubsen et al,
9 and
always choosing death (or disease specific death) if
such a component had been used. The observers also
rated the gradient of importance for components, and
looked for any discussion of the rationale for the com-
posite.
Reporting of composite We assessed the consistency of
thecomponentsofthecompositebetweentheabstract,
methods, and results; determined whether data were
reported for all components (that is, so that they
could be used in a meta-analysis); judged whether the
components were of similar importance; and evalu-
ated whether the conclusion presented in the abstract
or the discussion section suggested that the inter-
vention was effective for all the components of the
composite outcome rather than just for the composite.
Data analysis
We present descriptive statistics and used Fisher’s
exact test for analysis of binary data. We had planned
toestimateanaverageinflationfactor,basedonacom-
parison of the effect for the composite outcome and
thatforthemostclinicallyimportantoutcome,butrea-
lised that this was problematic (see Discussion).
8
Abstracts screened (n=212)
Trial reports potentially eligible (n=43)
Trials included in analysis (n=40)
Excluded based on text
  (n=13):
    Not a randomised
      clinical trial (n=1)
    Not binary outcome (n=4)
    More than two arms (n=1)
    Composite outcome is
      secondary (n=4)
    Incomplete data (n=2)
    Duplicate publication
      (n=1)
Excluded based on abstract
  (n=156):
    Not a randomised
      clinical trial (n=97)
    Not binary outcome (n=18)
    More than two arms (n=16)
    No composite outcome
      reported (n=7)
    Not in English (n=2)
    More than one exclusion
      criteria (n=16)
Excluded because not clear which
outcome is most important (n=3)
Fig 1 | Flow chart for inclusion of trials
Table 1 |Characteristics of 40 trials published in 2008
reporting composite outcomes
No (%) of trials
Clinical area:
Cardiovascular 29 (73)
Nephrology 3 (8)
Gynaecology 2 (5)
Other 6 (15)
Journal:
New England Journal of Medicine 6( 1 5 )
JAMA 4( 1 0 )
American Heart Journal 3 (8)
Lancet 3 (8)
BMJ 2 (5)
Circulation 2 (5)
Transplantation 2 (5)
Other 18 (45)
Funding:
Industry funding 16 (40)
Partly industry funding 8 (20)
No industry funding 7 (18)
Unclear 9 (23)
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Our searches identified 212 abstracts, 169 of which
were ineligible as described in fig 1. The remaining
43 articles were potentially eligible, but we excluded
three
w1–w3becauseitwasnotcleartouswhichoutcome
was most clinically important (which needed to be
identified for our reporting analysis). For example, a
trial that compared two methods of vein stripping
hadacompositeoutcomethatconsistedofhaematoma
in the thigh, ecchymosis, seroma, wound healingcom-
plications, wound infections, and phlebitis.
w1
Table 1 describes the characteristics of the 40
included trials,
w4–w43 which together randomised
110080 patients, with a median sample size of 1486
(interquartilerange213–4460).Thetwomostcommon
journals of publication were the New England Journal of
Medicine (n=6) and JAMA (n=4); 29 trials (73%) were on
cardiovascular topics. In 24 reports (60%) it was
declared that the trials were totally (n=16) or partially
(n=8) industry funded, seven trials did not receive
industry support, and for nine trials the funding was
not clear.
Composite definition
The composite outcomes had a median of three com-
ponents (range 2–9). The most important component,
selectedby us,wasdeathor cardiovasculardeathin33
trials(83%),clinicalevents(suchasincontinencesymp-
toms, respiratory distress, phlebitis, or arrhythmia) in
sixtrials(15%),andhospitaladmissioninonetrial(3%)
(table 2).
Our assessment of composite
Wejudgedthatthecomponentswereofsimilarimpor-
tance in seven trials (18%): infiltration or phlebitis
w4;
death or chronic lung disease in preterm babies
w28;
no reflow, slow flow, and ventricular arrhythmia
w15;
death, graft loss, or acute rejection
w13 w23 w29; and total
mortality, clinical re-infarction, or disabling stroke.
w30
Five trials (13%) were questionable, as they combined
death and non-fatal myocardial infarction without
defining non-fatal myocardial infarction—so it might
have included silent events.
w12 w17 w20 w26 w31
In the remaining 28 trials (70%), the components
werenotofsimilarimportance:20trialshadcombined
death with hospital admission (or procedures that
required hospital admission, such as revascularisa-
tion), and eight trials had other problems
w5 w6 w16 w19
w22 w25 w32 w33 (such as combining death and silent myo-
cardial infarctions,
w22 combining death with new exer-
tional angina and transient ischaemic attack,
w16 or
combining death with a doubling of serum creatinine
concentration from baseline
w33).
Author discussion of composite
Seven trial reports (18%) included a discussion related
to the rationale for the composite. Only one report,
about intravenous catheters, provided a rationale sup-
portingthe constructionofthe composite: “It hasbeen
argued that infiltration (easy to diagnose) may result
from unrecognised phlebitic changes to the vein wall
(hard to diagnose) leading to under-reporting of phle-
bitis. It is perhaps more useful to use the composite
measure of infiltration or phlebitis as it avoids any
potential for misdiagnosis.”
w4 The other six reports
only mentioned problems with the composite: three
notedthatthecomponentsdidnothavesimilarclinical
importance,
w6–w8 one that the composite had not been
validated for clinical relevance,
w5 one that the compo-
site was driven by the procedural outcome,
w9 and one
was problematic because one of its five components
(myocardialinfarction)favouredonedrugandanother
component (bleeding) favoured the other drug.
w10
Other definition problems
In four trials (10%), the trial authors explicitly stated
that they created the composite post hoc.
w22 w25–w27 In
threecases,theprespecifiedcompositewasnotstatisti-
cally significant, but the new, post hoc composite was,
suggesting cherry picking (see examples in box).
Reporting of composites
Inconsistent reporting of components
In13reports(33%),thedefinitionofthecompositeout-
come changed between the abstract, methods, and
resultssections.Foreighttrials,
w12 w14 w17–w22thereport-
ing problem was minor, involving inconsistent use of
modifiers—for example, whether a myocardial infarc-
tion
w12 w17 w18 w20 or a stroke
w22 was lethal, whether
deathsreferredtothosefromallcausesorfromspecific
disease,
w14 w21andreversalofthescale(apositivestress
test was later reported as a negative stress test
w19).
For five trials, the inconsistency was major, as the
components were not the same throughout the trial
report.
w7 w8 w16 w23 w24 For example, in one trial, death
was added as a new component.
w7 In another trial,
Table 2 |Definition and reporting of composite outcomes used in 40 trials published in 2008
No (%) of trials
Composite definition
Most important component:
Death (all causes or disease specific) 33 (83)
Clinical outcome (hospital admission or symptom) 7 (17)
Clinical importance of components:
Similar 7 (18)
Might be similar 5 (13)
Not similar 28 (70)
Author discussion of composite outcome: 7 (18)
No discussion 33 (83)
Explains rationale for composite 1 (3)
Acknowledges problems with composite 6 (15)
Reporting of composite
Components consistent between abstract, methods, and results 27 (68)
Components inconsistent: 13 (33)
Major inconsistency (components added or deleted) 5 (13)
Minor inconsistency (ambiguous wording change) 8 (20)
Data for components provided 31 (78)
Data for components not provided: 9 (23)
Missing data 2 (5)
Ambiguous data 7 (18)
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after renal transplantation,
w23 the abstract concluded
there was “no evidence of an increased risk of poorer
performance” (based on 1 v 0 severe acute rejections).
But, using the definition in the methods and data in a
table, we found an increased risk of rejection (14 v 6
acute rejections, P=0.06). In a third trial
w16 the results
table omitted data for two components, sudden death
andnewlydevelopedexertionalangina,whilethetable
provided data for an outcome not mentioned in the
definition of the composite, stable angina.
Missing data for components
In two cardiovascular trials, data on the most impor-
tantcomponentweremissing.Inone,
w14twoofustried
tocalculatedeathsfromcardiovascularcausesfromthe
categories presented in a table, but we arrived at two
different answers and cannot determine which set of
numbers,ifeither,iscorrect(fig2).Theothertrialpro-
videdatablewithallthecomponents,
w7but,asnotedin
the trial report, only those events that occurred first
were tabulated. It was therefore not possible to see
how many patients died, as only those deaths that
occurred before any other events (such as gastro-
intestinal, eye, or skin complications) were reported.
In three other cardiovascular trials, the number of
events for the components added up exactly to the
number of composite events (see webtable 2 on
bmj.com). The reports provided no way of knowing
whether these data reflected only the first events (as
above) or that no patient had more than one
event.
w15–w17 We believe that only first events were
reported, as it is implausible, for example, that no one
hadanginaoratransientischaemicattackbeforedying
from cardiovascular causes.
w16
In another four trials, numerical data could not be
extracted. In one trial, the authors reported 31 “com-
bined events” in a group with only 29 patients.
w11 In
anothertrial,therewerevastlymoreeventsinthecom-
ponent outcomes than in the composite outcome (an
impossibility since by definition patients experience
the composite if they experience any of the compo-
nents).
w5 In the third trial, the number of components
increased from three to eight after an interim analysis
showedfewereventsthananticipated,butwecouldnot
figureoutwhatthecompositewas,asthereportingwas
inconsistent.
w8 In the fourth trial,
w13 the data were
given as percentages, which led to inconsistencies: 11
versus12diedaccordingtothepercentagesbut11ver-
sus 14 according to a table, and graft losses were 23
versus 22 from the percentages but 15 versus 15 in
the table.
w13
Problems with reporting the role of chance
Consistent with problems about how clinical trials are
reported in general,
10 we found errors in the P values
reported. One of the trials reported the composite was
statistically significant (P=0.037)
w15 when it was not
(P=0.09 according to our calculation). In another trial,
there was an error in the opposite direction: the authors
reported that the most important outcome was not sig-
nificant(P=0.192)
w33wheninfactitwas;theintervention
was harmful, as it increased mortality significantly
(P=0.046, our calculation). Confidence intervals for the
components were not reported in 22 trials (55%).
Inadequate interpretation
In 22 cases (55%), the conclusions of the abstract or the
discussion did not remind readers that the outcome was
a composite, and 33 conclusions (82%) did not specifi-
callysayiftherewas—orwasnot—asimilareffectonthe
most important component (see examples in fig 3). Sta-
tistically significant results were reported in three trials
for the most important component (death or cardio-
vascular death), in one trial for both the most important
componentandthecompositeoutcome(butinopposite
directions, as the effect was beneficial for the composite
of death or non-fatal myocardial infarction and harmful
for death
w12), and in 16 trials for the compositeoutcome
only. In 11 of these 16 trials, the abstract conclusions
falsely implied the effect applied also tothe most impor-
tant component: two listed all components of the com-
posite using “and” (see webtable 3 on bmj.com), and
nine referred to the composite as a class of events (for
example, “reduced the incidence of major cardio-
vascular events”
w14).
Selected examples of problems in defining composite outcomes
Composite outcome was not prespecified (cherry picking)
w25
Abstract—“a composite end point of myocardial infarction, stroke, or sudden death.”
Text (methodssection)—Describes a different composite: “a composite cardiovascular end
point consisting of sudden death, myocardial infarction, angina, or chest pain.” It adds
another one: “We wrote a more detailed protocol before the analysis of vascular events,
and this added an additional composite end point of myocardial infarction, stroke, or
sudden death, as this has become the commonly used end point in such analyses.”
Our comment—The abstract made no mention of the prespecified composite. The
additional composite was reported, but its post hoc nature was not mentioned. Of note,
the prespecified composite was not statistically significant (P=0.68), but the post hoc
composite was (P=0.008).
Inconsistent definition throughout the paper
w8
Methods section—“A composite including bone-grafting, implant exchange or removal
because of a broken nail or deep infection, and debridement of bone and soft tissue
because of deep infection, dynamization of the fracture (i.e., interlocking screw removal to
allow fracture-site compression with weight bearing) in the operating room or in the
outpatient clinic; removal of locking screws because of hardware breakage or loosening;
autodynamization (spontaneous screw breakage leading to dynamization at the fracture
site prior to healing); fasciotomy; and drainage of hematomas.”
Results section—“Bone-grafting in a patient with full cortical continuity, implant exchange
for union in a patient with full cortical continuity, implant removal for union in a patient
with full cortical continuity, reoperation in response to a local infection, bone-grafting in a
patient with a fracture gap of <1 cm, implant exchange in a patient with a fracture gap of
<1 cm, implant removal in a patient with a fracture gap of <1 cm, dynamization in a patient
with a fracture gap of <1 cm, removal of locking screws due to hardware breakage or
loosening of screws, treatment of wound necrosis in the presence of infection, fasciotomy
forthe treatment ofintraoperative compartment syndrome, fasciotomy for thetreatmentof
postoperative compartment syndrome, autodynamization (failure of the screw-bone
construct [i.e., broken or bent screws] that dynamizes the fracture), draining of a
hematoma, failure of the construct (broken nail).”
Our comment—Change in the number of components (from 8 in methods section to 11 in
results section) is a major inconsistency.
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Accountingfor inconsistencies in definition ofcompo-
nents and in reported numbers, only 24 of the 40 trials
(60%) provided reliable estimates for both the compo-
site and its components. Of the 12 trials that had com-
ponents of similar, or possibly similar, clinical
importance, only six trials provided reliable estima-
tes.
w4 w26 w28–w31
DISCUSSION
Trialswithcompositeoutcomesareoftenproblematic,
characterisedbyalackoflogicbehindtheconstruction
of the composites, inconsistent and unclear reporting,
posthocchangestothecomposites,andcherrypicking
of favourable outcomes or combinations of outcomes.
Guidance for authors aimed at ensuring that the com-
ponents are appropriate and avoid misleading results
and statements
135-9 have existed for years but seem to
have had little effect on the trials we examined, which
were from 2008.
Composite outcomes create a substantial opportu-
nity for post hoc changes. In a cohort of 102 trial pro-
tocols and subsequent publications, changes to at least
oneprimaryoutcomehadoccurredin63%ofthetrials,
and not in a single case had the report acknowledged
the modification.
11 It is therefore likely that many of
the composite outcomes we studied, which were all
primary outcomes, had been modified post hoc with-
out acknowledging this. In fact, a survey of cardio-
vascular trials showed marked asymmetry in the
distributionofPvaluesaroundP=0.05,suggestingpos-
siblepublicationbiasorthatindividualoutcomeswere
selected for inclusion in the composite to ensure statis-
tical significance.
8
Because components can be combined in so many
ways, it is easy to find significant results. In one of the
trials we included,
w16 the composite consisted of eight
cardiovascular end points, but there were also second-
ary composites that consisted of “combinations of pri-
mary end points as well as death from any cause.”
These combinations were not specified, but nine end
points can be combined, as two or more components,
in 502 possible ways (2
9−1(empty sample)−9(samples
with only one component)). The result for the compo-
site was not statistically significant, but the abstract
noted that the hazard ratio was 0.10 for a combined
end point of fatal coronary events and fatal cerebro-
vascular events (P=0.0037)—that is, a cherry picked
result. One would expect 25 of 502 possible combina-
tions to be significant purely by chance.
We found other examples of cherry picking. A trial
of percutaneous coronary intervention had four com-
ponents in the composite (death, myocardial infarc-
tion, urgent revascularisation of target vessel, and
major bleeding), but the relative risk and the confi-
dence interval were shown only for major bleeding,
where the experimental drug had an advantage, and
the last sentence in the conclusions in the abstract
was: “it did significantly reduce the incidence of
major bleeding.”
w10
We also encountered the most ingenious way of get-
ting rid of dead patients that we have ever seen.
w7
Deaths in a cardiovascular trial were listed only if
they occurred before anything else. Thus, one might
avoid deaths by including a component that precedes
death, such as chest pain.
It is also problematic that death was so commonly
included in composites, as it provides the lowest
eventratesandthesmallesttreatmenteffects.
5Further-
more, death can mean many things. It was total mor-
tality in seven trials, some form of cardiovascular
mortality in 17 trials, death with no further specifica-
tioninseventrials,andsuddendeathinonetrial.Since
total mortality is the only mortality outcome that is
guaranteed free from bias, we suggest that cardio-
vascular trialists use this outcome. A particularly
revealing example of data dredging is the Anturane
reinfarctiontrial.
12Afterpublicationofpositiveresults,
researchers at the US Food and Drug Administration
foundthatthetrial’sclassificationofcauseofdeathwas
“hopelessly unreliable.”
13 Cardiac deaths were classi-
fied into three groups—sudden deaths, myocardial
infarction, or other cardiac event—and nearly all the
errors in assigning cause of death favoured the
End point
Primary end point
Non-fatal myocardial infarction
Any myocardial infarction
Non-fatal stroke
Any stroke
Arterial revascularisation
Hospitalisation for unstable angina
Arterial revascularisation or hospitalisation for unstable angina
Myocardial infarction, stroke, or confirmed death from cardiovascular causes
Death on known date
Any death
Rosuvastatin
(n=8901)
142
22
31
30
33
76
16
76
83
190
198
Placebo
(n=8901)
251
62
68
58
64
143
27
143
157
235
247
Solution 1
Myocardial infarction, stroke, or confirmed death from cardiovascular causes
minus     Non-fatal myocardial infarction
minus     Non-fatal stroke
Death from cardiovascular causes
Rosuvastatin
83
-22
-30
31
Placebo
157
-62
-58
37
Solution 2
Any myocardial infarction
minus     Non-fatal myocardial infarction
plus         Any stroke
minus     Non-fatal stroke
Death from cardiovascular causes
Rosuvastatin
31
-22
+33
-30
12
Placebo
68
-62
+64
-58
12
The composite outcome consisted of myocardial infarction, stroke, arterial revascularisation,
hospitalisation for unstable angina, or death from cardiovascular causes, but deaths from
cardiovascular causes were not presented (in the table or the article)
How data were presented:
Question: How many deaths were there from cardiovascular causes? (try for yourself before going to
  the possible solutions)
Possible solutions: 
Fig 2 | Example of a confusing presentation of a composite outcome
w14
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death, the major finding of the trial.
The inclusion of clinician driven outcomes in the
composite, such as admission to hospital, is proble-
matic because they are far less important than dying
and because they are highly vulnerable to bias in
non-blinded trials. Nine of the 20 trials that had used
hospital admission were not blinded for the clini-
cians.
w7 w11 w21 w27 w34–w38 Another survey showed that
the inclusionof aclinician drivenoutcomewaspredic-
tive of a statistically significant result for the primary
composite outcome (odds ratio 2.24 (95% confidence
interval 1.15 to 4.34), P=0.02).
3
In addition to these problems, which we found
equally often in the best general medical journals
w7
w10 w14 w16 w18 w20 w25 as in specialty journals, it is com-
monlydifficulttoexplainwhataneffectonacomposite
outcomereally means. Thisis particularly so when the
effect on the composite outcome and on the most
important single outcome go in different directions,
as in the trial where the drug significantly decreased
thecompositeendpointofnon-fatalmyocardialinfarc-
tion and death but increased significantly the number
of deaths.
w12 A hypothetical conversation may illus-
trate the challenge:
“Mr Smith, here is a drug that will reduce your
combined risk of getting a heart attack that will not
kill you, or of dying.”
“Doctor, I am not sure I quite understood you, but
please give me this drug.”
“But I should also mention that the drug will
increase your risk of dying.”
“Didn’t you just tell me that the drug would
decrease my risk of dying? I am confused.”
Limitations of study
Asweaimedatprovidingageneralpictureoftheuseof
composite outcomes, we included all clinical areas.
Because we relied on electronic searches, it is possible
thathandsearchingjournalarticleswouldhaveyielded
more trials. Most of the trials we identified were on
cardiovascular topics, which is partly because compo-
sites are so common in this area and partly because all
terms in our search strategy contained either “compo-
site” or “combined” (see webtable 1 on bmj.com). For
some diseases, composites may not be described as
such. In cancer trials, for example, it is common to
usedisease-freesurvival,whichmeansthatthepatients
neither had tumour recurrence nordied. Such compo-
sites can be misleading, as some treatments reduce the
risk of tumour recurrence while increasing the risk of
death—for example, radiotherapy given to low risk
patients such as women who had their breast cancer
detectedatscreening.
14AnotherexampleisHIVinfec-
tion,whereitiscommontouseacompositeofdeathor
timetofirstAIDSdefiningevent.Itwouldthereforebe
interesting to perform studies of composite outcomes
in other disease areas.
We had planned to estimate an average “inflation”
factor,comparingtheeffectforthecompositewiththat
for the most clinically important outcome, but it is not
straightforward how one should analyse the data.
815
The observations are not independent, as the most
important outcome contributes to the composite, and
ratiosbetweenrelativerisksareveryunstablewhenthe
denominator is close to zero (division almost by
zero).
15 It is therefore not feasible to compare results
within trials before pooling in a meta-analysis.
Primary outcome
Patients with any event (could have >1 event)
Death from cardiovascular causes
Aortic valve replacement surgery
Congestive heart failure as a result of
  progression of aortic stenosis
Non-fatal myocardial infarction
Coronary-artery bypass grafting
Percutaneous coronary intervention
Hospitalisation for unstable angina
Non-haemorrhagic stroke
Conclusion: “...a combination pill ... did not reduce a combined end point of total
  cardiovascular events among high-risk women.”
w18 
Hazard ratio
(95% CI)
0.96 (0.83 to 1.12)
0.83 (0.56 to 1.22)
1.00 (0.56 to 1.22)
1.09 (0.62 to 1.92)
0.64 (0.35 to 1.17)
0.68 (0.50 to 0.93)
0.46 (0.20 to 1.06)
0.61 (0.20 to 1.86)
1.12 (0.68 to 1.87)
P value
0.59
0.34
0.97
0.77
0.15
0.02
NA
NA
0.65
Placebo
(n=929)
355 (38.2)
56 (6.0)
278 (29.9)
23 (2.5)
26 (2.8)
100 (10.8)
17 (1.8)
8 (0.9)
29 (3.1)
Simvastatin
plus ezetimibe
(n=8901)
333 (35.3)
47 (5.0)
267 (28.3)
25 (2.6)
17 (1.8)
69 (7.3)
8 (0.8)
5 (0.5)
25 (2.6)
Composite endpoint:
  No-reflow
  Slow-flow
  Ventricular arrhythmia
Control
(n=36)
8 (22.2%)
2 (5.2%)
4 (10.4%)
2 (5.2%)
P value
0.037
0.538
0.155
0.146
Nicorandil
(n=37)
2 (5.4%)
1 (2.7%)
1 (2.7%)
0
Do
Prespecified primary and secondary outcomes and death
w41 Do
Conclusion: “...rosuvastatin significantly reduced the incidence of major cardiovascular
  events.”w14 
Our comment: Can mislead readers to believe that all components are equally important,
  even though there was an important gradient, from hospitalisation to cardiovascular death.
Conclusion: “administration of intracoronary nicorandil reduced the occurrence of no-reflow,
  slow reflow, and reperfusion arrhythmia.”
w15 
Our comment: Misleads readers to believe the effect is present, and the same, for all
  components. P value for composite is also wrong (see text)
Don’t
PCI data and laboratory findings of the 73 patients Don’t
Remind readers that result is based on a composite outcome 
Report data for all components
“There was no evidence that this treatment strategy increased mortality. Intensive glucose
 control significantly reduced the primary composite outcome of major macrovascular or
 microvascular events, mainly as a consequence of a reduction in nephropathy. There was no
 separately significant reduction in major macrovascular events, although a modest benefit
 could not be ruled out.”w36
Do
State whether the intervention has a similar effect on all components, or specify on which
 components there is an effect (specifically mentioning the most important component)
“A composite endpoint of grade 1–3 ongoing pain and either grade 3–4 induration (≥25 mm)
  or grade 2–4 nodules/cysts (>20 mm). The composite endpoint has not been validated for
  clinical relevance.”
w5
Do
Highlight inherent problems associated with composite outcomes 
Fig 3 | Selected examples of composite outcomes being handled well (“Do”)o rp o o r l y( “Don’t”)
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For trialists—Composite outcomes should generally be
avoided,astheiruseleadstomuchconfusionandbias.
If composites are used, trialists should follow pub-
lished guidance
135-9: only combine components of
similar clinical importance, take care to define them
consistently throughout the paper, analyse the prespe-
cified composite, and list results for all components
(not just the first occurring events) in a table with con-
fidence intervals. Ideally, to avoid flaws in reporting
and misleading perceptions about treatment effects,
9
every single combination of events should be shown
in a table. Thus, for five components, there would
need to be 31 (2
5−1) lines in the table of outcomes.
For meta-analysts—Meta-analysts should be careful
when extracting data from trial reports with composite
outcomes. We found many possibilities for data extra-
ction errors—forexample,subtledifferencesinwording
maymeanthatwhatisbeingreportedmightnotbewhat
the meta-analyst thinks it means, or what was described
in the methods section or elsewhere in the paper.
Furthermore, it can be only those events that occurred
first that are tabulated. Meta-analysis of composite out-
comes is inappropriate, as the likelihood of cherry pick-
ing is too high; only the components should be used.
For editors—Composite outcomes are easily misun-
derstood by readers. Editors should insist that conclu-
sions explicitly remind readers that the result is based
onacompositeoutcome.Toavoidmisleadingreaders,
editors should ensure that conclusions state whether
the interventionhad a similareffectonall components
or specify on which components there was an effect,
specifically mentioning the most important compo-
nent (see fig 3). Finally, as the potential for post hoc
changes is so large, editors should post the trial proto-
col and the raw data on the journal’s website.
Conclusions
Theuseofcompositeoutcomesintrialsisproblematic.
Componentsareoftenunreasonablycombined,incon-
sistently defined, and inadequately reported. These
problems will leave many readers confused, often
with an exaggerated perception of how well inter-
ventions work.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
 Whentrialresults arereportedasacomposite outcome,theeffect isoftensmallestfor the
mostimportantcomponentoftheoutcomeandbiggestforthelessimportantcomponents
 Clinician driven outcomes are predictive of a statistically significant result for the
composite outcome
 Individual outcomes may be selected for inclusion in the composite to ensure statistical
significance
WHAT THIS STUDY ADDS
 Changes in the definition of composite outcomes during a trial are common and suggest
biased reporting
 Pivotal data are often missing, ambiguous, or uninterpretable
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